Evidence map›Paper›PMID 29476107›Full record

ArticleScientific reports2018

Scalable Culturing of Primary Human Glioblastoma Tumor-Initiating Cells with a Cell-Friendly Culture System.

Qiang Li, Haishuang Lin, Jack Rauch, Loic P Deleyrolle, Brent A Reynolds, Hendrik J Viljoen, Chi Zhang, Chi Zhang, Linxia Gu, Erika Van Wyk and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Article
  2. Understanding Glioblastoma Dynamics Using 3D Organoids and Engineered Extracellular Matrix.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Alginate microfibers as therapeutic delivery scaffolds and tissue mimics.Experimental biology and medicine (Maywood, N.J.) · 2022
    Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Frontiers in oncology · 2021
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Qiang LiDepartment of Chemical and Biomolecular Engineering, University of Nebraska, Lincoln, Nebraska, USA.
Haishuang LinDepartment of Chemical and Biomolecular Engineering, University of Nebraska, Lincoln, Nebraska, USA.
Jack RauchDepartment of Chemical and Biomolecular Engineering, University of Nebraska, Lincoln, Nebraska, USA.
Loic P DeleyrolleDepartment of Neurosurgery, University of Florida College of Medicine, McKnight Brain Institute, Gainesville, Florida, USA.
Brent A ReynoldsDepartment of Neurosurgery, University of Florida College of Medicine, McKnight Brain Institute, Gainesville, Florida, USA.
Hendrik J ViljoenDepartment of Chemical and Biomolecular Engineering, University of Nebraska, Lincoln, Nebraska, USA.
Chi ZhangSchool of Biological Science, University of Nebraska, Lincoln, Nebraska, USA.
Chi ZhangDepartment of Radiation Oncology, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Linxia GuDepartment of Mechanical & Materials Engineering, University of Nebraska, Lincoln, Nebraska, USA.ORCID 0000-0003-2637-0299
Erika Van WykCellGro Technologies, LLC, Adams, NE, USA.
Yuguo LeiDepartment of Chemical and Biomolecular Engineering, University of Nebraska, Lincoln, Nebraska, USA. ylei14@unl.edu.ORCID 0000-0002-7682-6912

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma is the most aggressive and deadly brain cancer. There is growing interest to develop drugs that specifically target to glioblastoma tumor-initiating cells (TICs). However, the cost-effective production of large numbers of high quality glioblastoma TICs for drug discovery with current cell culturing technologies remains very challenging. Here, we report a new method that cultures glioblastoma TICs in microscale alginate hydrogel tubes (or AlgTubes). The AlgTubes allowed long-term culturing (~50 days, 10 passages) of glioblastoma TICs with high growth rate (~700-fold expansion/14 days), high cell viability and high volumetric yield (~3.0 × 10

Indexed as

Cell Culture TechniquesAlginatesAnimalsBiomarkers, TumorBioreactorsBrain NeoplasmsCell DifferentiationCell ProliferationCell SurvivalEquipment DesignGene ExpressionGlial Fibrillary Acidic ProteinGlioblastomaHeterograftsHumansHydrogelsAlginatesBiomarkers, TumorGFAP protein, humanGlial Fibrillary Acidic ProteinHydrogelsNES protein, humanNestinOLIG2 protein, humanOligodendrocyte Transcription Factor 2SOX2 protein, humanSOXB1 Transcription FactorsTUBB3 protein, humanTubulin

Identifiers

PMID29476107
PMCPMC5824878

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.